(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Who is Artemis? Meet the Greek goddess who inspired NASA's return to the moon - 2'The Real Housewives of Rhode Island' 1st teaser trailer unveiled: Which Bachelor Nation star is part of the cast? And when does it premiere?
- 3A few Up-to-date Sacks - Stylish Young ladies Shouldn't Miss
- 4US FDA unveils new pathway to approve personalized therapies
- 5Islamabad: Iran allows 20 Pakistani ships through Strait of Hormuz
- 5 VIP Voice Exhibitions in Energized Movies
- 10 Distinct Kinds of Chinese Neighborhood Specialty Hot Pot
- Step in Style: A Survey of \Solace and Execution on the Track\ Running Shoes
- The Most Notable Design Brands of the 21st Hundred years
- Swap The Amalfi Coast For This Low-Cost Ligurian Seaside Town
- Instructions to Warmly greet Discretion and Thoughtfulness
- Extravagance SUVs for Seniors: Solace, Innovation, and Security
- The most effective method to Guarantee Simple Availability in Seniors' SUVs
- Inconceivable Spots To Stargaze All over The Planet
